Activity and expression pattern of NF-xB /p65 in peripheral blood from hepatocellular carcinoma patients - link to hypoxia inducible factor -1α

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 16, 2014, Pages 6911-6917

  Gaballah, Hanaa Hibishy ^a   Zakaria, Soha Said ^a   Ismail, Saber Abdelrahman ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Binding activity; HCC; Hypoxia inducible factor one alpha; Liver cirrhosis; NF xB

Indexed keywords

DNA BINDING PROTEIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BINDING; RELA PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA;

BIOSYNTHESIS; BLOOD; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84926219040     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.16.6911     Document Type: Article

References (49)

1. Abdelaziz AO, Elbaz TM, Shousha HI, et al (2014). Survival and prognostic factors for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Asian Pac J Cancer Prev, 15, 3915-20.
2. Balermpas P, Michel Y, Wagenblast J, et al (2013). Nuclear NF-κB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy. Int J Radiat Oncol Biol Phys, 86, 785-90.
3. Beale G, Chattopadhyay D, Gray J, et al (2008). AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer, 18, 8-200.
4. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
5. Bruix J, Sherman M (2005). Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of hepatocellular carcinoma. Hepatology, 42, 1208-36.
6. Cheng ZX, Wang DW, Liu T, et al (2014). Effects of the HIF-1a and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells. Oncol Rep, 31, 1891-8.
7. Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A (2007). The transcription factor nuclear factorkappa B and cancer. Clin Oncol, 19, 154-61.
8. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52.
9. Gong JP, Liu CA, Wu CX, et al (2002). Nuclear factor kB activity in patients with acute severe cholangitis. World J Gastroenterol, 8, 346-9.
10. González-Ramos R, Rocco J, Rojas C, et al (2012). Physiologic activation of nuclear factor kappa-B in the endometrium during the menstrual cycle is altered in endometriosis patients. Fertil Steril, 97, 645-51.
11. Görlach A, Bonello S (2008). The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison. Biochem J, 412, 17-9.
12. Haruki K, Shiba H, Fujiwara Y, et al (2013). Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-a gene therapy for hepatocellular carcinoma in mice. Surgery, 154, 468-78.
13. Hoesel B, Schmid JA (2013). The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer, 12, 86.
14. Hung CH, Lee CM, Kuo FY, et al (2008). Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C. Liver Int, 28, 339-4.
15. Johnson PJ (2001). The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis, 5, 145-59.
16. Kim HR, Lee SH, Jung G (2010). The hepatitis B viral X protein activates NF-kappaB signaling pathway through the upregulation of TBK1. FEBS Lett, 584, 525-30.
17. Lee SC, Tan HT, Chung MC (2014). Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol, 20, 3112-24.
18. Lei JY, Wang WT, Yan LN. (2013). Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol, 19, 6077-83.
19. Lenihan CR, Taylor CT (2013). The impact of hypoxia on cell death pathways. Biochem Soc Trans, 41, 657-63.
20. Li S, Yao D, Wang L, et al (2011). Expression characteristics of hypoxia-inducible factor-1a and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon, 11, 821-8.
21. Li WW, Wang QC, Song XW, et al (2012). Correlation of the expression of NF-κB p65 and hepatic fibrosis in hepatitis patients. Zhonghua Yi Xue Za Zhi, 17, 1886-8.
22. Luedde T, Schwabe RF (2011). NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 8, 108-18.
23. Mimeault M, Batra SK (2013). Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer-and metastasis-initiating cells. J Cell Mol Med, 17, 30-54.
24. Ramakrishna G, Rastogi A, Trehanpati N, et al (2013). From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer, 2, 367-383.
25. Ren S, Zhang S, Li M, et al (2013). NF-κB/p65 and c-Rel subunits promote phagocytosis and cytokine secretion by splenic macrophages in cirrhotic patients with hypersplenism. Int J Biochem Cell Biol, 45, 335-43.
26. Rosmorduc O, Housset C (2010). Hypoxia: a link between fibrogenesis, angiogenesis and carcinogenesis in liver disease. Semin Liver Dis, 30, 258-70.
27. Sakurai T, Kudo M (2013). Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma. Liver Cancer, 2, 365-6.
28. Sarkar DK, Jana D, Patil PS, et al (2013). Role of NF-κB as a prognostic marker in breast cancer: a pilot study in Indian patients. Indian J Surg Oncol, 4, 242-7.
29. Semenza GL (2013). HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest, 123, 3664-71.
30. Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60.
31. Sun W, Guo MM, Han P, et al (2012). Id-1 and the p65 subunit of NF-κB promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis, 33, 810-7.
32. Taylor CT, Cummins EP (2009). The role of NF-kappaB in hypoxia-induced gene expression. Ann N Y Acad Sci, 1177, 178-84.
33. Tiwari M, Mikuni S, Muto H, Kinjo M (2013). Determination of dissociation constant of the NFκB p50/p65 heterodimer using fluorescence cross-correlation spectroscopy in the living cell. Biochem Biophys Res Commun, 5, 430-5.
34. Troeger JS, Schwabe RF (2011). Hypoxia and hypoxia-inducible factor 1a: potential links between angiogenesis and fibrogenesis in hepatic stellate cells. Liver Int, 31, 143-5.
35. Unwith S, Zhao H, Hennah L, Ma D (2014). The potential role of HIF on tumour progression and dissemination. Int J Cancer, doi: 10.1002/ijc.28889.
36. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al (2006). Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription PCR, immuno-histochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res, 12, 3249-56
37. Van Loo G, Beyaert R. (2011). Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res Ther, 31, 221.
38. Wang L1, Kang F, Li J, Zhang J, Shan B (2013). Overexpression of p65 attenuates celecoxib-induced cell death in MDAMB-231 human breast cancer cell line. Cancer Cell Int, 13, 14.
39. Wilkins T, Malcolm JK, Raina D, et al (2010), Hepatitis C: diagnosis and treatment. American Family Physician, 81, 1351-7.
40. Wong LL, Lam IP, Wong TY, et al (2013). IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation. PLoS One, 8, e68843.
41. Wu W, Yao D, Wang Y, et al (2010). Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumour Biol, 31, 605-11.
42. Wu W, Yao DF, Qiu LW, et al (2009). Characteristics of hepatic nuclear-transcription factor-kappa B expression and quantitative analysis in rat hepatocarcinogenesis. Hepatobiliary Pancreat Dis Int, 8, 504-9.
43. Xia JT, Chen LZ, Jian WH, et al (2014). MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med, 12, 33.
44. Yokoo H, Yasuda J, Nakanishi K, et al (2011). Clinicopathological significance of nuclear factor-κB activation in hepatocellular carcinoma. Hepatol Res, 41, 240-9.
45. Yoshida T, Hashimura M, Mastumoto T, et al (2013). Transcriptional upregulation of HIF-1a by NF-κB/p65 and its associations with β-catenin/p300 complexes in endometrial carcinoma cells. Lab Invest, 93, 1184-93.
46. Zekri AR, Hassan ZK, Bahnassy AA, et al (2012). Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev, 13, 5433-8.
47. Zhang J, Zhang DL, Jiao XL, Dong Q (2013). S100A4 regulates migration and invasion in hepatocellular carcinoma HepG2 cells via NF-κB-dependent MMP-9 signal. Eur Rev Med Pharmacol Sci, 17, 2372-82.
48. Zhang F, Wang Q, Ye L, et al (2010). Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-κB/p65 in hepatoma cells. J Med Virol, 82, 920-8.
49. Zhou L, Liu C, Meng FD, et al (2012). Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pac J Cancer Prev, 13, 483-6.